Cargando…
Early-Phase Adverse Effects and Management of Liposomal Amikacin Inhalation for Refractory Mycobacterium avium Complex Lung Disease in Real-World Settings
PURPOSE: Amikacin liposome inhalation suspension (ALIS), which efficiently allows amikacin to reach the pulmonary periphery for effect while minimising systemic adverse effects, was recently approved for treating Mycobacterium avium complex (MAC) infections. The international Phase 3 open-label clin...
Autores principales: | Morita, Atsuho, Namkoong, Ho, Yagi, Kazuma, Asakura, Takanori, Hosoya, Makoto, Tanaka, Hiromu, Lee, Ho, Ogawa, Takunori, Kusumoto, Tatsuya, Azekawa, Shuhei, Nakagawara, Kensuke, Kamata, Hirofumi, Ishii, Makoto, Fukunaga, Koichi, Ozawa, Hiroyuki, Hasegawa, Naoki |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9342928/ https://www.ncbi.nlm.nih.gov/pubmed/35924016 http://dx.doi.org/10.2147/IDR.S373783 |
Ejemplares similares
-
Laryngitis after inhalation of liposomal amikacin
por: Morita, Atsuho, et al.
Publicado: (2022) -
Longitudinal significance of six-minute walk test in patients with nontuberculous mycobacterial pulmonary disease: an observational study
por: Morita, Atsuho, et al.
Publicado: (2023) -
Nasopharyngeal Mycobacterium abscessus Infection: A Case Report and Literature Review
por: Kaji, Masanori, et al.
Publicado: (2023) -
Osteoporosis in nontuberculous mycobacterial pulmonary disease: a cross-sectional study
por: Tanaka, Hiromu, et al.
Publicado: (2022) -
Association between six-minute walk test parameters and the health-related quality of life in patients with pulmonary Mycobacterium avium complex disease
por: Yagi, Kazuma, et al.
Publicado: (2018)